MDT - Medtronic plc
Avidity Partners Management LP lessened its holdings in Medtronic PLC (NYSE: MDT) by 7.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 100,000 shares of the medical technology company's stock after selling 7,600 shares during the period. Medtronic comprises 1.7% of Avidity Partners Management LP's
Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Medtronic could finally be on the cusp of a long-awaited turnaround.
Medtronic (MDT) closed at $84.22 in the latest trading session, marking a +1.21% move from the prior day.
Orchestra BioMed is approaching pivotal trial readouts for AVIM Therapy and Virtue SAB, both with strong success potential. OBIO operates as an innovation and clinical development platform for medical devices, relying on Medtronic and Terumo for commercialization. Medtronic and Terumo have invested a combined $146 million, with OBIO's $220 million valuation reflecting a modest premium to strategic funding and with significant potential upside as catalysts approach.
Medtronic (MDT) reached $82.35 at the closing of the latest trading day, reflecting a -1.13% change compared to its last close.
Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedure FDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic procedures from Medtronic, advances a precise, predictable, and personalized future for surgery GALWAY, Ireland, July 21, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, is presenting an early look at its next-generation compute platform for the operating room. Touch Surgery™ Aide — an AI-native surgical computing platform that powers the Touch Surgery™ ecosystem — enables real-time artificial intelligence during procedures.
Andra AP fonden lowered its stake in Medtronic PLC (NYSE: MDT) by 3.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,329 shares of the medical technology company's stock after selling 10,400 shares during the quarter. Andra AP fonden's holdings in
GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026. A news release containing summary financial information will be issued at 5:45 a.m.
Decker Wealth Management LLC bought a new position in shares of Medtronic PLC (NYSE: MDT) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 58,614 shares of the medical technology company's stock, valued at approximately $5,079,000. Other
Allspring Global Investments Holdings LLC cut its stake in Medtronic PLC (NYSE: MDT) by 16.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 885,098 shares of the medical technology company's stock after selling 178,782 shares during the quarter. Allspring Global
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹ GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management.
Medtronic (MDT) reached $83.87 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.
I initiate coverage on Medtronic, highlighting its status as a leading medtech name with premium margins. MDT offers an attractive diversification opportunity, combining consistent performance with accelerated revenue growth. The stock trades at undervalued levels, supporting a long-term bullish thesis and a defensive investment approach.
Medtronic plc is rated buy with a $92 price target, reflecting conservative fiscal 2027 guidance and resilient growth platforms. Fiscal 2026 delivered $36.4B in revenue, the strongest growth in a decade, led by Cardiovascular and ablation solutions outpacing market rates. Guidance for fiscal 2027 excludes potential catalysts—MiniMed separation, tariff refunds, and Blackstone payment relief—implying room for upside surprises.
Medtronic is a dividend aristocrat with a near-decade high yield, making it an attractive long-term income opportunity. The company is experiencing strong revenue growth, driven by its leading positions in cardiovascular and neuroscience medical devices. While current free cash flow payout ratios are sustainable, investors should monitor future dividend growth rates closely.
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Medtronic (MDT) reached $78.23 at the closing of the latest trading day, reflecting a -3.34% change compared to its last close.
On June 30, 2026, Medtronic PLC (MDT) shares fell 3.3% today, bringing the current price to $78.23. The stock has traded between $73.31 and $106.33 over the pas